CITF Research Results

CITF Research Results2021-10-12T16:15:35-04:00

Booster doses stimulate strong antibody responses, including in older adults

While two doses of COVID-19 vaccine can prevent serious illness in most cases, vaccine-induced immune responses decline naturally over time, which leads to an increased risk of breakthrough infections. A pre-print, not-yet peer-reviewed, from CITF-funded researchers Dr. Mark Brockman of Simon Fraser University, Dr. Zabrina Brumme of Simon Fraser University and the BC Centre for Excellence in HIV/AIDS, and Dr. Marc Romney, from Providence [...]

January 17, 2022|Long-term care & seniors|

Background rates for blood clotting events in Ontario provide context for COVID-19 vaccine safety assessment

In order to help public health authorities and clinicians to contextualize observed events of vaccine-induced immune thrombotic thrombocytopenia (VITT) - an extremely rare but serious blood clot following immunization with the AstraZeneca/Vaxzevria COVID-19 vaccine - the Canadian Immunization Research Network (CIRN), including CITF-funded researcher Dr. Jeff Kwong, sought to estimate background rates of selected thromboembolic and coagulation disorders in Ontario from 2015-2020. Without the [...]

January 10, 2022|General vaccine surveillance|

A viral-vector COVID-19 vaccine candidate under development

Researchers, including Dr. Ryan Troyer from the University of Western Ontario, who is funded by the CITF, are developing a new vaccine that uses a harmless virus-based delivery vehicle. This approach enables the SARS-CoV-2 spike protein to be presented to the immune system, thereby training it to recognize and prevent SARS-CoV-2 infection. The vaccine candidate was demonstrated to be capable of providing protection from [...]

January 10, 2022|Immune science|

How can serosurveys be used in the vaccine era?

In this preprint, not yet peer reviewed, led by SeroTracker, CITF-funded researchers and CITF Secretariat employees, the authors present an approach to help interpret serosurvey results and distinguish between infection-acquired and vaccine-induced immunity. Making the distinction between how infection and vaccine induced  immunity can help guide public health officials worldwide in their strategy for providing vaccines against COVID-19. Before broad vaccination campaigns, serosurveys were [...]

January 10, 2022|Other|

Study measures vaccine effectiveness against Omicron infection in Ontario

In this not-yet peer reviewed pre-print, led by CITF-funded researcher Dr. Jeff Kwong on behalf of the Canadian Immunization Research Network (CIRN), researchers evaluated the effectiveness of mRNA vaccines against the Omicron variant in Ontario. They found that two doses of COVID-19 vaccines were not protective against Omicron infection. However, more than seven days after a third dose of an mRNA vaccine, effectiveness against [...]

January 10, 2022|General vaccine surveillance|

Boosting immunity in the elderly

In a pre-print, not yet peer reviewed, study led by CITF-funded researchers Drs. Andrew Costa and Dawn Bowdish at McMaster University, people in retirement or nursing homes had repeat blood samples taken to measure immunity after the second and third doses of SARS-COV-2 mRNA vaccines. Researchers found that the third vaccine dose brought about levels of neutralization capacity that were much higher than what [...]

January 10, 2022|Long-term care & seniors|

Canadian Blood Services data reveal evidence of antibody wane among adult population

The latest Canadian Blood Services (CBS) report, from October 2021, indicates that 98% of blood donors sampled had antibodies to SARS-CoV-2. This number is largely driven by immunization with at least one vaccine dose, as infection-acquired seroprevalence stayed low, at 4.3%. Results also reveal a downward trend in the mean levels of antibodies across all age groups between September and October, supporting the need [...]

January 10, 2022|General population studies|

Dried Blood Spot Assays: A Review

Many Canadian serosurveys have opted to use dried blood spot (DBS) tests as a practical means to study population-level SARS-CoV-2 seroprevalence. Tens of thousands of Canadians have received DBS kits in the mail. In this article, now published in PLOS ONE, researchers, including several CITF members, set out to determine which of the available DBS assays performed the best. A DBS test can be [...]

December 20, 2021|Optimization of immunologic testing|

Immunity to SARS-CoV-2 following infection persists for at least 9 months

The exact mechanisms of immune protection to SARS-CoV-2 are still unclear and researchers around the world continue to attempt to address this critical question. In an article now published in The Journal of Immunology, Dr. Tania Watts from the University of Toronto, unravels the characteristics and extent of B cell and T cell immune responses after recovery from COVID-19, finding that there was evidence [...]

December 20, 2021|Immune science|
Go to Top